Ocugen, Inc. (NASDAQ:OCGN) Q4 2025 Earnings Call Transcript March 4, 2026 Ocugen, Inc. reports earnings inline with expectations. Reported EPS is $-0.06 EPS, expectations were $-0.06. Operator: Good ...
Ocugen’s model fair value holds at US$11.43 per share, with no change to the underlying price target despite fresh clinical and financing updates. That stability reflects a cautious analyst stance ...
OCU400 is the lead modifier gene therapy candidate for retinitis pigmentosa. Enrollment is complete in the Phase III liMeliGhT study, with 140 patients enrolled. Ocugen is targeting the start of a ...
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Ocugen (OCGN) one of those stocks right now? A quick glance ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Operator: Good morning, and welcome to Ocugen's Second Quarter 2026 Financial Results and Business Update. [Operator Instructions] I will now turn the call over to Chris Clark, Ocugen's Head of ...
Ocugen Inc (NASDAQ:OCGN) shares are trading higher by 25.6% to $2.06 during Monday’s session. The stock is trading higher, potentially on upward momentum, after the Third Circuit Court of Appeals last ...
Pan American Silver (PAAS) came out with quarterly earnings of $0.73 per share, missing the Zacks Consensus Estimate of $0.84 ...
The average one-year price target for Ocugen (NasdaqCM:OCGN) has been revised to $8.36 / share. This is an increase of 26.15% from the prior estimate of $6.63 dated September 27, 2025. The price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results